Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 8220-8225
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8220
Figure 1
Figure 1 Responses of lung and brain lesions to afatinib. A: Baseline before treatment; B: After 3 mo of afatinib treatment: Lung lesion responded partially and brain lesion was stable; C: After 10 mo of afatinib treatment: Lung lesion remained stable and brain lesion progressed. Only the target brain metastatic lesion was displayed and indicated by the orange arrow.
Figure 2
Figure 2 Treatment history and timeline of the patient’s best objective response. A: Treatment history and timeline; B: Illustration of epidermal growth factor receptor L833F mutation in cis with L861Q mutation. BAC: Bevacizumab + pemetrexed + carboplatin; ARMS PCR: Amplification refractory mutation system polymerase chain reaction; NGS: Next generation sequencing; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; SD: Stable disease; PD: Progressive disease.
Figure 3
Figure 3 Responses of lung and brain lesions to osimertinib + bevacizumab regimen. A: At docetaxel + bevacizumab failure, before osimertinib treatment; B: 2 mo after treatment initiation, both lung and brain lesions were stable; C: 3 mo after treatment, both lesions remained stable. RAH: Right/anterior/head; RPF: Right/posterior/feet; RP: Right/posterior; LA: Left/anterior; RHA: Right/head/anterior; LFP: Left/feet/posterior.